Ruiz-Ruiz F J, Ruiz-Laiglesia F J, Lasierra-Diaz P, Samperiz-Legarre P, Morales-Rull J L, Sánchez-Marteles M, Amores M, Perez-Calvo J I
Internal Medicine Department, Hospital Clínico Universitario Lozano Blesa, Avenida San Juan Bosco 15, Zaragoza, Spain.
Singapore Med J. 2007 Jun;48(6):532-6.
Interleukin-6 (IL-6) has been identified as a predictor of death, new heart failure (HF) episodes and need for heart transplantation in patients with advanced HF. The aim of this study was to examine the relationship between plasma IL-6 levels in patients with decompensated HF and either survival or new admissions due to HF.
We studied 111 patients admitted due to decompensated HF. Long-term survival was assessed from the day of admission to the hospital to the day of death or new admissions due to HF.
The mean IL-6 concentration was 90 +/- 115 pg/ml (range 1.5-743 pg/ml). There were no differences in IL-6 concentration with regard to age, gender and cause of HF. At the end of follow-up period, 22 patients (20 percent) had died due to causes related to HF and 54 patients (48 percent) had been readmitted to the hospital due to new HF episodes. Using regression analyses, serum IL-6 levels were not identified as a prognostic factor. Systolic dysfunction, previous diagnosis of HF and diabetes mellitus were independent predictors of death.
These findings suggest that a single measurement of serum IL-6 in patients with decompensated HF lacks clinical usefulness in long-term follow-up.
白细胞介素-6（IL-6）已被确定为晚期心力衰竭患者死亡、新发心力衰竭（HF）发作及心脏移植需求的预测指标。本研究旨在探讨失代偿性心力衰竭患者血浆IL-6水平与生存率或因心力衰竭再次入院之间的关系。
我们研究了111例因失代偿性心力衰竭入院的患者。从入院之日至死亡或因心力衰竭再次入院之日评估长期生存率。
IL-6的平均浓度为90±115 pg/ml（范围为1.5 - 743 pg/ml）。IL-6浓度在年龄、性别和心力衰竭病因方面无差异。随访期末，22例患者（20%）因与心力衰竭相关的原因死亡，54例患者（48%）因新发心力衰竭发作再次入院。通过回归分析，血清IL-6水平未被确定为预后因素。收缩功能障碍、既往心力衰竭诊断和糖尿病是死亡的独立预测因素。
这些发现表明，对失代偿性心力衰竭患者单次测量血清IL-6在长期随访中缺乏临床实用性。
